Want to see PL:CTX full AI Analyst Report?
Captor Therapeutics SA (CTX) Stock Statistics & Valuation Metrics
Total Valuation
Captor Therapeutics SA has a market cap or net worth of PLN 349.93M. The enterprise value is PLN 396.61M.
- Market Cap
- PLN 349.93M
- Enterprise Value
- PLN 396.61M
Share Statistics
Captor Therapeutics SA has 6,362,331 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 6,362,331
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Captor Therapeutics SA’s return on equity (ROE) is -1.79 and return on invested capital (ROIC) is -195.82%.
- Return on Equity (ROE)
- -1.79
- Return on Assets (ROA)
- -1.05
- Return on Invested Capital (ROIC)
- -195.82%
- Return on Capital Employed (ROCE)
- -2.12
- Revenue Per Employee
- 56.83K
- Profits Per Employee
- -512.16K
- Employee Count
- 82
- Asset Turnover
- 0.12
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Captor Therapeutics SA is -6.96. Captor Therapeutics SA’s PEG ratio is 2.00.
- PE Ratio
- -6.96
- PS Ratio
- 170.49
- PB Ratio
- 5.21
- Price to FCF
- -4.64
- Price to Operating Cash Flow
- -4.62
- PEG Ratio
- 2.00
Income Statement
In the last 12 months, Captor Therapeutics SA had revenue of 4.66M and earned -42.00M in profits. Earnings per share was -7.61.
- Revenue
- 4.66M
- Gross Profit
- -652.00K
- Operating Income
- -53.21M
- Pretax Income
- -42.00M
- Net Income
- -42.00M
- EBITDA
- -48.84M
- Earnings Per Share (EPS)
- -7.61
Cash Flow
In the last 12 months, operating cash flow was -73.39M and capital expenditures -363,000, giving a free cash flow of -73.75M billion.
- Operating Cash Flow
- -73.39M
- Free Cash Flow
- -73.75M
- Free Cash Flow per Share
- -11.75
Dividends & Yields
Captor Therapeutics SA pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -21.56%
- Earnings Yield
- -13.06%
Stock Price Statistics
- Beta
- 0.36
- 52-Week Price Change
- 15.63%
- 50-Day Moving Average
- 65.18
- 200-Day Moving Average
- 74.75
- Relative Strength Index (RSI)
- 39.05
- Average Volume (3m)
- 5,119
Important Dates
Captor Therapeutics SA upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Sep 03, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Financial Position
Captor Therapeutics SA as a current ratio of 2.27, with Debt / Equity ratio of 15.23%
- Current Ratio
- 2.27
- Quick Ratio
- 2.27
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.15
- Interest Coverage Ratio
- -188.01
Taxes
In the past 12 months, Captor Therapeutics SA has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Captor Therapeutics SA EV to EBITDA ratio is -7.45, with an EV/FCF ratio of -4.64.
- EV to Sales
- 170.62
- EV to EBITDA
- -7.45
- EV to Free Cash Flow
- -4.64
- EV to Operating Cash Flow
- -4.66
Balance Sheet
Captor Therapeutics SA has PLN 71.50M in cash and marketable securities with PLN 2.66M in debt, giving a net cash position of PLN 68.84M billion.
- Cash & Marketable Securities
- PLN 71.50M
- Total Debt
- PLN 2.66M
- Net Cash
- PLN 68.84M
- Net Cash Per Share
- PLN 10.82
- Tangible Book Value Per Share
- PLN 10.20
Margins
Gross margin is 106.78%, with operating margin of -2534.30%, and net profit margin of -2207.63%.
- Gross Margin
- 106.78%
- Operating Margin
- -2534.30%
- Pretax Margin
- -2206.28%
- Net Profit Margin
- -2207.63%
- EBITDA Margin
- -2290.93%
- EBIT Margin
- -2470.94%
Analyst Forecast
The average price target for Captor Therapeutics SA is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -81.93%
- EPS Growth Forecast
- -3.31%
Scores
- Smart Score
- ―
- AI Score
- 44.1
